Merck KGaA announced that it has entered into a collaboration and licensing agreement with Domain Therapeutics to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. This collaboration strengthens combination strategy in immuno-oncology, and underscores Merck KGaA science-driven approach to discovering and developing novel compounds through both internal capabilities and external collaborations. Adenosine receptor antagonists are small molecules thought to slow tumor progression and improve the response to combination immunotherapies by inhibiting adenosine - a compound generated by cancer cells that inhibits anti-tumor responses by binding to T cells. The agreement will involve a close collaboration between Merck KGaA and Domain Therapeutics to develop and test new agents targeting key adenosine receptors. Merck KGaA, Darmstadt, Germany, will support research activities and gain worldwide rights to Domain Therapeutics' next generation of adenosine receptor inhibitors.